EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

Blocking of IL-7R inhibited the upregulation of RAG expression by autoreactive B220 low B cells, thereby preventing receptor revision following antigen recognition. The ability to prevent the ...

B cells are prolific producers of these autoantibodies, and as such have been targeted by numerous antirheumatic therapies. One of these therapies, rituximab, a chimeric monoclonal antibody ...